Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 9;6(4):100710.
doi: 10.1016/j.adro.2021.100710. eCollection 2021 Jul-Aug.

Proton Reirradiation for Locoregionally Recurrent Breast Cancer

Affiliations

Proton Reirradiation for Locoregionally Recurrent Breast Cancer

Michael J LaRiviere et al. Adv Radiat Oncol. .

Abstract

Purpose: Local-regional recurrence (LRR) of breast cancer after prior adjuvant radiation (RT) can present a clinical challenge. Proton therapy is recommended by the American Society for Radiation Oncology in cases where reirrradiation is needed; however, data are limited. We present the toxicity and outcomes after reirradiation for local-regional recurrence of breast cancer with proton therapy.

Methods and materials: A single-institution retrospective review identified patients with the following criteria: LRR of breast cancer, prior photon radiation to the same region, proton beam reirradiation, and definitive intent. Surgery or systemic therapy at the time of recurrence was used when indicated. The log-rank test was used to compare Kaplan-Meier survival estimates. Kruskal-Wallis tests were performed to compare worst reported toxicities with clinical variables.

Results: The population included 27 patients with a history of prior radiation and treated with proton therapy for LRR between 2012 and 2019. The median interval between courses was 9.7 years. Proton reirradiation regimens included whole breast/chest wall (WB/CW) with regional nodal RT (22/27), nodal RT alone (2/27), or WB/CW alone (3/27). The median dose was 51 Gy, and the most common fractionation was 1.5 Gy twice daily. Median follow-up after reirradiation was 16.6 months. Acute grade 3 toxicities included dermatitis in 2 patients and breast pain in 2 patients. Grade 2 or higher late toxicities included 6 G2 rib fractures and 1 G2 brachial plexopathy, 1 G3 dermatitis, 1 G3 breast pain, and 1 G4 dermatitis. Twelve patients had new documented recurrences of which 1 was a second in-field LRR, and there were 7 deaths.

Conclusions: Proton salvage reirradiation to median 51 Gy in 1.5 Gy twice daily appears to be safe with acceptable acute and late toxicity, and effective with >95% local-regional control.

PubMed Disclaimer

Figures

Fig 1
Figure 1
Recurrence-free survival after reirradiation.
Fig 2
Figure 2
Overall survival after reirradiation. Patients are stratified by interval between initial and reirradiation courses, ≥2 years versus <2 years between radiation courses.
Fig 3
Figure 3
The chest wall appearance for 3 women treated with proton reirradiation at 1.5 Gy twice daily. (A) One year after 57 Gy, (B) 1.5 years after 51 Gy, and (C) 2 years after 51 Gy reirradiation.

Similar articles

Cited by

References

    1. Early Breast Cancer Trialists' Collaborative Group Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. - PMC - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–2135. - PMC - PubMed
    1. Aalders K, van Bommel AC, van Dalen T. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Can. 2016;63:118–126. - PubMed
    1. Holleczek B, Segmaier C, Radosa JC. Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis: Results from a registry-based study from Germany. BMC Cancer. 2019;19:520. - PMC - PubMed
    1. McBride A, Allen P, Woodward W. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392–398. - PubMed

LinkOut - more resources